Lexaria Bioscience Corp.

LEXX Nasdaq Healthcare · Pharmaceutical Preparations Kelowna, British Columbia, Canada lexariabioscience.com
$4.53
Mkt Cap 27.7M

Developer of the DehydraTECH drug-delivery technology platform that improves oral absorption of active pharmaceutical ingredients.

From the annual report

Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients ( APIs ) using our patented DehydraTECH TM drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. DehydraTECH can be used with a wide range of active molecules including glucagon-like peptide-1 drugs ( GLP-1 ) and glucose-dependent insulinotropic polypeptide drugs ( GIP ), vitamins, pain medications, hormones, antivirals, nicotine and its analogs, and cannabinoids. Our technology can be applied to a variety of therapeutic indications, including diabetes, weight loss, epilepsy, hypertension and heart disease. DehydraTECH can be implemented in a multitude of ingestible product formats including oral suspensions, tablets, capsules, foods, beverages, and oral pouches. It is suitable for use with a variety of product formats including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. DehydraTECH is a technology incorporated into the formulation and manufacturing process of new or existing orally ingestible products.

—
/100 Overall
Calculating score…
Running full analysis
📊 Key Metrics
Loading full analysis…
REVENUE TTM
$194.0K
FCF TTM
-$7.5M
Running full 6-factor analysis…